This Phase 1 study will evaluate the safety, tolerability, pharmacokinetics/pharmacodynamics (PK/PD), and clinical activity of KT-253 in adult patients with relapsed or refractory (R/R) high grade myeloid malignancies, acute lymphocytic leukemia (ALL), R/R lymphoma, myelofibrosis, and R/R solid tumors. The study will identify the pharmacologically optimal dose(s) (MTD) of KT-253 as the recommended Phase 2 dose (RP2D), based on all safety, PK, PD, and efficacy data.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Incidence and severity of adverse events
Timeframe: From the time of signing ICF through 30 days after last dose of study drug or prior to start of a new anticancer therapy
Maximum Tolerated Dose (MTD) and recommended Phase 2 dose (RP2D) in Patients
Timeframe: From the time of the first dose of study drug through 30 days after the last dose of study drug or prior to start of a new anticancer therapy